JAZZ PHARMACEUTICALS Reports Positive Second Quarter Financial Results for FY2023
August 11, 2023
☀️Earnings Overview
JAZZ PHARMACEUTICALS ($NASDAQ:JAZZ) released their financial performance for Q2 of FY2023, ended on June 30, 2023. Total revenue amounted to USD 957.3 million, a 2.6% rise from the same quarter last year. Net income was reported to be USD 104.4 million, significantly higher than the prior year’s USD 34.7 million, an increase of 201.7%.
Price History
On Wednesday, JAZZ PHARMACEUTICALS reported positive second quarter financial results for FY2023, and the stock opened at $132.6 and closed at $133.0, up by 0.6% from prior closing price of 132.2. This is a positive development for the company as they achieved their financial goals in the second quarter. All these factors point towards a successful second quarter for JAZZ PHARMACEUTICALS.
The increase in revenue, operating income, and net income shows that the company is on track to achieve its goals and improve its financial performance. The stock closing price of $133.0 is evidence of the confidence investors have in the company’s future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Jazz Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 3.76k | -86.51 | 5.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Jazz Pharmaceuticals. More…
| Operations | Investing | Financing |
| 1.38k | -410.34 | -395.91 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Jazz Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 11.26k | 7.73k | 55.61 |
Key Ratios Snapshot
Some of the financial key ratios for Jazz Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.3% | -2.4% | 1.0% |
| FCF Margin | ROE | ROA |
| 26.2% | 0.7% | 0.2% |
Analysis
At GoodWhale, we have conducted an analysis of the wellbeing of JAZZ PHARMACEUTICALS. Based on our Risk Rating, JAZZ PHARMACEUTICALS is a high risk investment in terms of the financial and business aspects. Our analysis has exposed four risk warnings in the income sheet, balance sheet, cashflow statement, and non-financial areas. If you register with us, you can check out the details of these warnings. We believe that being aware of these risks can help you make better investment decisions and protect your portfolio. More…
Peers
The company has a diversified portfolio of products in central nervous system, hematology/oncology, inflammation and other therapeutic areas. Jazz Pharmaceuticals‘ competitors include Nurix Therapeutics Inc, Incyte Corp, and Poxel SA.
– Nurix Therapeutics Inc ($NASDAQ:NRIX)
Nurix Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on harnessing the body’s own natural mechanisms to regulate protein function for the treatment of cancer and other diseases. The company’s lead product candidate is a first-in-class, orally available, small molecule inhibitor of the proteasome, which is in development for the treatment of relapsed or refractory multiple myeloma. Nurix was founded by Robert L. Gould, Ph.D. and Bruce A. Cohen, M.D. in December 2001 and is headquartered in San Francisco, CA.
– Incyte Corp ($NASDAQ:INCY)
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. The company’s market cap is 15.34B as of 2022 and its ROE is 9.54%. Incyte’s products include Jakafi, Iclusig, and Jakavi. Jakafi is used to treat myelofibrosis and polycythemia vera, two rare blood disorders. Iclusig is used to treat leukemias, including chronic myeloid leukemia andPhiladelphia chromosome-positive acute lymphoblastic leukemia. Jakavi is used to treat myelofibrosis, polycythemia vera, and essential thrombocythemia.
– Poxel SA ($LTS:0RA2)
Poxel SA is a French pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of diabetes and obesity. The company has a market capitalization of 43.37 million as of 2022 and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.
Summary
JAZZ PHARMACEUTICALS had a successful second quarter for FY2023, with total revenue increasing 2.6% year-over-year to USD 957.3 million and a corresponding 201.7% increase in net income to USD 104.4 million. This strong performance suggests that JAZZ PHARMACEUTICALS is a good investment opportunity for those looking to capitalize on its growth potential. In particular, investors should be encouraged by the company’s focus on product innovation, cost-effectiveness, and expanding global presence. Additionally, the company’s recently announced partnerships and acquisitions suggest that JAZZ PHARMACEUTICALS is well positioned to capitalize on long-term growth opportunities.
Related Posts
Recent Posts
